{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,14]],"date-time":"2025-06-14T04:17:10Z","timestamp":1749874630724},"reference-count":27,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2014,10]]},"DOI":"10.1097\/ftd.0000000000000055","type":"journal-article","created":{"date-parts":[[2014,5,28]],"date-time":"2014-05-28T15:43:37Z","timestamp":1401291817000},"page":"576-583","source":"Crossref","is-referenced-by-count":14,"title":["Plasma Concentrations of Tadalafil in Children With Pulmonary Arterial Hypertension"],"prefix":"10.1097","volume":"36","author":[{"given":"Hiroyuki","family":"Kohno","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fukiko","family":"Ichida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keiichi","family":"Hirono","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sayaka","family":"Ozawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naoki","family":"Yoshimura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tsuneyuki","family":"Nakamura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chisato","family":"Akita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuya","family":"Ishida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masato","family":"Taguchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-4-20210129","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1161\/CIRCULATIONAHA.110.016667","article-title":". A randomized, double-blind, placebo-controlled, dose-ranging study of oral sildenafil citrate in treatment-naive children with pulmonary arterial hypertension.","volume":"125","author":"Barst","year":"2012","journal-title":"Circulation"},{"key":"R2-4-20210129","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1183\/09059180.00003512","article-title":"A critical analysis of survival in pulmonary arterial hypertension.","volume":"21","author":"OCallaghan","year":"2012","journal-title":"Eur Respir Rev"},{"key":"R3-4-20210129","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1007\/s00246-013-0688-2","article-title":". Food and drug administration (FDA) postmarket reported side effects and adverse events associated with pulmonary hypertension therapy in pediatric patients.","volume":"34","author":"Maxey","year":"2013","journal-title":"Pediatr Cardiol"},{"key":"R5-4-20210129","doi-asserted-by":"crossref","first-page":"F109","DOI":"10.1136\/adc.2009.168336","article-title":". Sildenafil exposure in neonates with pulmonary hypertension after administration via a nasogastric tube.","volume":"95","author":"Ahsman","year":"2010","journal-title":"Arch Dis Child Fetal Neonatal Ed"},{"key":"R6-4-20210129","first-page":"1488","article-title":". Differences in hemodynamic and oxygenation responses to three different phosphodiesterase-5 inhibitors in patients with pulmonary arterial hypertension: a randomized prospective study.","volume":"44","author":"Ghofrani","year":"2004","journal-title":"J Am Coll Cardiol"},{"key":"R7-4-20210129","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1177\/0091270008315315","article-title":". Pharmacokinetic interaction between tadalafil and bosentan in healthy male subjects.","volume":"48","author":"Wrishko","year":"2008","journal-title":"J Clin Pharmacol"},{"key":"R8-4-20210129","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1111\/j.1365-2125.2005.02553.x","article-title":". Tadalafil pharmacokinetics in healthy subjects.","volume":"61","author":"Forgue","year":"2006","journal-title":"Br J Clin Pharmacol"},{"issue":"suppl 1","key":"R9-4-20210129","first-page":"70","article-title":". Identification of the human cytochrome P450 (CYP) responsible for the formation of the major oxidative metabolite of tadalafil (Cialis).","volume":"36","author":"Ring","year":"2004","journal-title":"Drug Metab Rev"},{"key":"R10-4-20210129","first-page":"W5308","article-title":". Metabolism and excretion of tadalafil in healthy men after oral administrationof 100 mg 14C-tadalafil.","volume":"6","author":"Phillips","year":"2004","journal-title":"The AAPS J"},{"key":"R11-4-20210129","doi-asserted-by":"crossref","first-page":"280","DOI":"10.2133\/dmpk.DMPK-10-RG-113","article-title":". Pharmacokinetics of bosentan in routinely treated Japanese pediatric patients with pulmonary arterial hypertension.","volume":"26","author":"Taguchi","year":"2011","journal-title":"Drug Metab Pharmacokinet"},{"key":"R12-4-20210129","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1111\/j.1365-2125.2006.02726.x","article-title":". Effects of gender, age, diabetes mellitus and renal and hepatic impairment on tadalafil pharmacokinetics.","volume":"63","author":"Forgue","year":"2007","journal-title":"Br J Clin Pharmacol"},{"key":"R13-4-20210129","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1016\/j.juro.2012.03.115","article-title":". Avanafil, a potent and highly selective phosphodiesterase-5 inhibitor for erectile dysfunction.","volume":"188","author":"Kotera","year":"2012","journal-title":"J Urol"},{"key":"R14-4-20210129","doi-asserted-by":"crossref","first-page":"41406","DOI":"10.1074\/jbc.M112.389189","article-title":". Identification of amino acid residues responsible for the selectivity of tadalafil binding to two closely related phosphodiesterases, PDE5 and PDE6.","volume":"287","author":"Cahill","year":"2012","journal-title":"J Biol Chem"},{"key":"R15-4-20210129","doi-asserted-by":"crossref","first-page":"2122","DOI":"10.1111\/j.1743-6109.2012.02822.x","article-title":". Selectivity of avanafil, a PDE5 inhibitor for the treatment of erectile dysfunction: implications for clinical safety and improved tolerability.","volume":"9","author":"Wang","year":"2012","journal-title":"J Sex Med"},{"key":"R16-4-20210129","doi-asserted-by":"crossref","first-page":"2891","DOI":"10.1016\/j.jchromb.2010.07.022","article-title":". A simple and sensitive HPLC fluorescence method for determination of tadalafil in mouse plasma.","volume":"878","author":"Farthing","year":"2010","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci"},{"key":"R17-4-20210129","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1007\/s10157-012-0616-4","article-title":". Population pharmacokinetics of mizoribine in pediatric recipients of renal transplantation.","volume":"16","author":"Ishida","year":"2012","journal-title":"Clin Exp Nephrol"},{"key":"R18-4-20210129","first-page":"590","article-title":". New equations to estimate GFR in children with CKD.","volume":"20","author":"Schwartz","year":"2006","journal-title":"J Am Soc Nephrol"},{"key":"R19-4-20210129","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1007\/BF01061870","article-title":"Evaluation of methods for estimating population pharmacokinetic parameters. III. Monoexponential model: routine clinical pharmacokinetic data.","volume":"11","author":"Sheiner","year":"1983","journal-title":"J Pharmacokinet Biopharm"},{"key":"R20-4-20210129","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1248\/bpb.29.772","article-title":". Multiple regression analysis of pharmacogenetic variability of carvedilol disposition in 54 healthy Japanese volunteers.","volume":"29","author":"Honda","year":"2006","journal-title":"Biol Pharm Bull"},{"key":"R22-4-20210129","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1007\/s00228-007-0297-1","article-title":". Tadalafil population pharmacokinetics in patients with erectile dysfunction.","volume":"63","author":"Troconiz","year":"2007","journal-title":"Eur J Clin Pharmacol"},{"key":"R23-4-20210129","doi-asserted-by":"crossref","first-page":"528","DOI":"10.18433\/J35P59","article-title":"Effects of experimental hyperlipidemia on the pharmacokinetics of tadalafil in rats.","volume":"15","author":"Lee","year":"2012","journal-title":"J Pharm Pharm Sci"},{"key":"R24-4-20210129","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/S0014-2999(02)02075-7","article-title":". Bosentan, a dual endothelin receptor antagonist, activates the pregnane X nuclear receptor.","volume":"450","author":"van Giersbergen","year":"2002","journal-title":"Eur J Pharmacol"},{"key":"R25-4-20210129","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1177\/00912709922008344","article-title":". Multiple-dose pharmacokinetics, safety, and tolerability of bosentan, an endothelin receptor antagonist, in healthy male volunteers.","volume":"39","author":"Weber","year":"1999","journal-title":"J Clin Pharmacol"},{"key":"R26-4-20210129","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1007\/BF00852829","article-title":"Holliday MA, al-Dahwi A, et al.. Expressing glomerular filtration rate in children.","volume":"5","author":"Heilbron","year":"1991","journal-title":"Pediatr Nephrol"},{"key":"R27-4-20210129","doi-asserted-by":"crossref","first-page":"1658","DOI":"10.1007\/s11095-012-0690-z","article-title":". Hepatocellular necrosis, fibrosis and microsomal activity determine the hepatic pharmacokinetics of basic drugs in right-heart-failure-induced liver damage.","volume":"29","author":"Li","year":"2012","journal-title":"Pharm Res"},{"key":"R28-4-20210129","doi-asserted-by":"crossref","first-page":"S307","DOI":"10.2131\/jts.34.SP307","article-title":"Essentials for starting a pediatric clinical study (1): pharmacokinetics in children.","volume":"34","author":"Yokoi","year":"2009","journal-title":"J Toxicol Sci"},{"key":"R29-4-20210129","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1007\/s00246-012-0180-4","article-title":"Initial experience with tadalafil in pediatric pulmonary arterial hypertension.","volume":"33","author":"Takatsuki","year":"2012","journal-title":"Pediatr Cardiol"}],"container-title":["Therapeutic Drug Monitoring"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/FTD.0000000000000055","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,14]],"date-time":"2021-05-14T00:28:16Z","timestamp":1620952096000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00007691-201410000-00004"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,10]]},"references-count":27,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2014]]}},"URL":"https:\/\/doi.org\/10.1097\/ftd.0000000000000055","relation":{},"ISSN":["0163-4356"],"issn-type":[{"value":"0163-4356","type":"print"}],"subject":[],"published":{"date-parts":[[2014,10]]}}}